These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 31599815)

  • 1. Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.
    Ismail A; Sharrack B; Saccardi R; Moore JJ; Snowden JA
    Curr Opin Support Palliat Care; 2019 Dec; 13(4):394-401. PubMed ID: 31599815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis: a Review of Current Literature and Future Directions for Transplant Haematologists and Oncologists.
    Das J; Sharrack B; Snowden JA
    Curr Hematol Malig Rep; 2019 Apr; 14(2):127-135. PubMed ID: 30828772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
    Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis.
    Gottschlich KN; Zolic-Karlsson Z; Aas E; Kvistad SAS; Bø L; Torkildsen Ø; Lehmann AK
    Mult Scler Relat Disord; 2024 Apr; 84():105507. PubMed ID: 38412758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances.
    Mariottini A; De Matteis E; Cencioni MT; Muraro PA
    Curr Neurol Neurosci Rep; 2023 Sep; 23(9):507-520. PubMed ID: 37589918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT).
    Burman J; Kirgizov K; Carlson K; Badoglio M; Mancardi GL; De Luca G; Casanova B; Ouyang J; Bembeeva R; Haas J; Bader P; Snowden J; Farge D
    Bone Marrow Transplant; 2017 Aug; 52(8):1133-1137. PubMed ID: 28319075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
    Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T
    Ther Adv Neurol Disord; 2023; 16():17562864231180730. PubMed ID: 37780055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multiple sclerosis: interventions to halt disease : Which patients can be considered for autologous stem cell transplantation].
    Willison AG; Meuth SG
    Nervenarzt; 2022 Oct; 93(10):987-999. PubMed ID: 35951049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE).
    Sharrack B; Saccardi R; Alexander T; Badoglio M; Burman J; Farge D; Greco R; Jessop H; Kazmi M; Kirgizov K; Labopin M; Mancardi G; Martin R; Moore J; Muraro PA; Rovira M; Sormani MP; Snowden JA;
    Bone Marrow Transplant; 2020 Feb; 55(2):283-306. PubMed ID: 31558790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation.
    Gakis G; Angelopoulos I; Panagoulias I; Mouzaki A
    Autoimmun Rev; 2024 Feb; 23(2):103480. PubMed ID: 38008300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how.
    Szczechowski L; Śmiłowski M; Helbig G; Krawczyk-Kuliś M; Kyrcz-Krzemień S
    Int J Neurosci; 2016 Oct; 126(10):867-71. PubMed ID: 26577419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.
    Mancardi G; Sormani MP; Muraro PA; Boffa G; Saccardi R
    Mult Scler; 2018 Mar; 24(3):245-255. PubMed ID: 29125439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
    Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
    Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis.
    Mariottini A; Nozzoli C; Carli I; Landi F; Gigli V; Repice AM; Ipponi A; Cecchi M; Boncompagni R; Saccardi R; Massacesi L
    Neurol Sci; 2024 Jul; 45(7):3379-3387. PubMed ID: 38277051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.
    Mariottini A; Bulgarini G; Forci B; Innocenti C; Mealli F; Mattei A; Ceccarelli C; Repice AM; Barilaro A; Mechi C; Saccardi R; Massacesi L
    Eur J Neurol; 2022 Jun; 29(6):1708-1718. PubMed ID: 35146841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
    Bose G; Thebault S; Rush CA; Atkins HL; Freedman MS
    Mult Scler; 2021 Feb; 27(2):167-173. PubMed ID: 32364422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economics of hematopoietic stem cell transplant in immune-mediated neurologic autoimmune diseases.
    Hughes SL; Prettyjohns MJ; Snowden JA; Sharrack B
    Handb Clin Neurol; 2024; 202():279-294. PubMed ID: 39111914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
    Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
    Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis.
    Ge F; Lin H; Li Z; Chang T
    Neurol Sci; 2019 Mar; 40(3):479-487. PubMed ID: 30535563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.